Steroid Avoidance or Withdrawal After Renal Transplantation Increases the Risk of Acute Rejection but Decreases Cardiovascular Risk. A Meta-Analysis
The DOI matches its Crossref record; 112 of the 113 references it cites were found in a registry or an index.
Abstract
Introduction The morbidity related to long-term steroid therapy has led to continued interest in withdrawal of steroids from immunosuppressant regimens after renal transplantation. A number of recent trials have provided long-term information regarding the risks and benefits of steroid avoidance or withdrawal (SAW). Methods A literature search was performed using Ovid Medline, Embase, the Cochrane Library, and the Transplant Library. Randomized controlled trials comparing a maintenance steroid group with complete avoidance or withdrawal of steroids were selected. All studies were assessed for methodological quality. Trials were pooled by meta-analysis to provide summary effects (relative risk [RR] or weighted mean difference) with 95% confidence intervals (CI). Results Thirty-four studies including 5,637 patients met the inclusion criteria. SAW regimens significantly increased the risk of acute rejection (AR) over maintenance steroids (RR 1.56, CI 1.31-1.87, P Conclusion Despite an increase in the risk of AR with SAW protocols, there is only a small effect on graft function with no measurable effect on graft or patient survival. There are significant benefits in cardiovascular risk profiles after SAW. SAW protocols would seem justified with current immunosuppressive protocols in low-risk recipients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Other more unique risk factors in this population include genetic polymorphisms, polycystic kidney disease, hepatitis C, and cytomegalovirus status.1579–1581”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1579]
In the citing paper
“An increasing body of new literature points to the association of immune checkpoint inhibitors with new-onset hyperglycemia and DM.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1579]
In the citing paper
“At this time, most of the literature is in the form of case reports demonstrating hyperglycemia, new-onset diabetes, and DKA, either with or without autoimmune markers of T1D.1579,1600–1605”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1579]
Citations
Cites
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · cited 1×
“Heterogeneity was quantified using the I(2) test, which describes the percentage of total variation across the studies that is due to heterogeneity rather than chance (17).”
MethodAssessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582 · cited 1×
“Quality was assessed both by means of the Jadad score (a score of 3 or greater is considered good quality) and a description of allocation concealment and analysis based on intention-totreat (15).”
MethodParmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802 · cited 2×
“2 (46) 57±20 (25) 66±33 (42) 47±17 (49) Maintenance Mean ± sd (N) 58.”
MethodInteraction revisited: the difference between two estimates.
Altman, D. G., & Bland, J. M. (2003) · BMJ · doi:10.1136/bmj.326.7382.219 · Cited by 3,203 · cited 2×
“Subgroups were compared using the interaction method described by Altman and Bland (28), with a significance level of P less than 0.”
InfluentialRosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036 · cited 3×
“2 (42) 161±65 (44) Maintenance Mean ± sd (N) 184.”
ResultImputing missing standard deviations in meta-analyses can provide accurate results
Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P., & Watanabe, N. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.06.006 · Cited by 1,568 · cited 1×
“Otherwise, a pooled standard deviation was calculated for all similar studies in the current meta-analysis and applied to studies with missing values (27).”
MethodLong-term survival in renal transplant recipients with graft function
Ojo, A. O., Hanson, J. A., Wolfe, R. A., Leichtman, A. B., Agodoa, L. Y., & Port, F. K. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00816.x · Cited by 810 · cited 2×
“Death with a functioning graft is an important cause of graft loss after renal transplantation, accounting for more than 40% of graft losses in one registry analysis (2).”
BackgroundWoodle, E. S., First, M. R., Pirsch, J., Shihab, F., Gaber, A. O., & Van Veldhuisen, P. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e318187d1da · Cited by 474
A Meta-Analysis of Immunosuppression Withdrawal Trials in Renal Transplantation
KASISKE, B. L., CHAKKERA, H. A., LOUIS, T. A., & MA, J. Z. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v11101910 · Cited by 392
Experience in Renal Transplantation
Starzl, T. E. (1965) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196505000-00064 · Cited by 363
Research works printed but not linked: 41
- Tan, 2006, Safety and efficacy of steroid withdrawal in modern triple immunosuppressant: A systematic review [Chinese]., Chin J Evid Based Med, 6, 273
- Vincenti, 2005, 3 months interim results of a 12-month study with enteric-coated mycophenolate sodium (EC-MPS, Myfortic®), basiliximab, and neoral C-2 comparing different steroid protocols in de novo kidney recipients [abstract]., J Am Soc Nephrol, 16, 236a
- Walker, 2005, Preliminary results of a 12-month study with enteric-coated mycophenolate sodium (EC-MPS), basiliximab, and neoral C-2 comparing two investigational steroid regimens (without steroids or short-term use of steroids) with standard steroid treatment in de novo kidney recipients [abstract]., Nephrology, 10, A214
- Vincenti, 2006, Metabolic effects of steroid avoidance or early steroid withdrawal: 12-month results of a randomised trial in de novo renal transplant patients receiving cyclosporine, enteric-coated mycophenolate sodium (EC-MPS) and basiliximab [abstract]., Am J Transplant, 6, 483
- Schena, 2006, 12-month results of a prospective, randomised trial of steroid avoidance, steroid withdrawal and standard steroids in de novo renal transplant patients receiving cyclosporine, enteric-coated mycophenolate sodium (EC-MPS) and basiliximab [abstract]., Am J Transplant, 6, 84
- Vincenti, 2005, Preliminary 3-month results comparing immunosuppressive regimens of enteric-coated mycophenolate sodium (EC- MPS) without steroids vs short-term use of steroids vs standard steroid treatment including basiliximab, and neoral C-2 in de novo kidney recipients abstract., Am J Transplant, 5, 548
- Walker, 2007, Comparison of metabolic parameters in renal transplant patients randomised to steroid avoidance, steroid withdrawal or standard steroids within a 12 month randomised multicentre trial [abstract]., Transplant Soc Aust N Z, 32
- Ing, 2007, Bone mineral density changes in a prospective randomized trial of steroid withdrawal in kidney transplant recipients abstract., Am J Transplant, 7, 310
- Stiller, 1983, The requirements for maintenance steroids in cyclosporine-treated renal transplant recipients., Transplant Proc, 15, 2490
- De Vecchi, 1985, Need for steroid in cyclosporine (Cy) treated cadaveric renal transplant recipients (pts) [abstract]., Kidney Int, 28, 394
- Griffin, 1986, Renal transplantation without steroids: A controlled clinical trial., Transplant Proc, 18, 797
- Nott, 1985, Low-dose steroids do not augment cyclosporine immunosuppression but do diminish cyclosporine nephrotoxicity., Transplant Proc, 17, 1289
- Johnson, 1990, Prospective trials with cyclosporine monotherapy in cadaver renal transplantation., J Nephrol, 3, 47
- Tarantino, 2000, Long-term results of a randomized trial of 3 cyclosporine (CSA) regimens in cadaveric kidney allografts (TXC) [abstract]., Nephrol Dial Transplant, 15, 250
- Klinger, 2003, Large, prospective study evaluating steroid-free immunosuppression with tacrolimus/basiliximab and tacrolimus/MMF compared with tacrolimus/MMF/steroids in renal transplantation [abstract]., Nephrol Dial Transplant, 18, 788
- Kramer, 2003, Two steroid-free immunosuppressive regimens (basiliximab/tacrolimus and tacrolimus/MMF) in comparison to tacrolimus/MMF/steroid therapy after renal transplantation [abstract]., J Am Soc Nephrol, 14, 9a
- Kramer, 2004, 1-year follow-up of two steroid-free immunosuppressive regimens—Basiliximab/Tacrolimus and tacrolimus/MMF—In comparison to tacrolimus/MMF/steroids after renal transplantation [abstract]., J Am Soc Nephrol, 15, 289a
- Vitko, 2003, Comparison of two steroid-free regimens—Basiliximab/Tacrolimus and Tacrolimus/MMF—With Tacrolimus/MMF/Steroid Therapy After Renal Transplantation [abstract]., Am J Transplant, 3, 312
- Pankewycz, 2004, The clinical benefits of early steroid withdrawal (7 days) and utility of protocol biopsies at 1, 6 and 12 months in guiding steroid-free immunosuppressive therapy after renal transplantation [abstract]., Am J Transplant, 4, 579
- Pankewyez, 2003, Induction immunosuppression for renal transplantation using thymoglobulin, FK506 and mycophenolate mofetil allows for safe steroid withdrawal and eliminates the need for early protocol biopsies [abstract]., Am J Transplant, 3, 478
- Gaber, 2006, Characteristics of rejection in renal allografts following early corticosteroid withdrawal in a randomized controlled clinical trial: Results of a 3 year follow-up [abstract]., Transplantation, 82, 178
- Pirsch, 2006, Effect of steroid withdrawal on new onset diabetes after transplant: Results of a randomized double blinded placebo controlled trial [abstract]., Transplantation, 82, 355
- Woodle, 2007, A randomized double blind, placebo-controlled trial of early corticosteroid cessation versus chronic corticosteroids: Four year results [abstract]., Am J Transplant, 7
- Woodle, 2006, Comparison of T cell depleting and non-t cell depleting antibody induction therapy for early corticosteroid withdrawal regimens abstract., Transplantation, 82, 353
- Woodle, 2008, A randomsied double blind, placebo-controlled trial of early corticosteroid cessation versus chronic corticosteroids: Five year results., Am J Transplant, 8, 300
- Nematalla, 2007, Improving quality of life after steroid avoidance immunosuppression regimen in live donor renal allotransplant recipients—A prospective randomized controlled study single center experience (Two year follow up) [abstract]., Transpl Int, 20, 134
- Aswad, 1998, Steroid withdrawal in living related kidney transplant patients receiving FK506 [abstract]., Nephrol Dial Transplant, 13, A285
- Burke, 2001, Double-blind, placebo-controlled trial of steroid withdrawal in kidney transplant recipients with a cyclosporine/mycophenolate regimen-three year follow up [abstract]., Am J Transplant, 1, 296
- Francos, 2002, Double-blind, placebo-controlled, 3 year study of steroid withdrawal using a neoral and mycophenylate mofetil (MMF)-based immunosuppressive regimen in primary renal transplant recipients [abstract]., Am J Transplant, 2, 172
- Boletis, 2002, Steroids withdrawal in renal transplant recipients: A randomized controlled study [abstract]., Nephrol Dial Transplant, 17, 312
- Smak Gregoor, 2001, A prospective randomised study of withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone: 18 months follow-up data [abstract]., Am J Transplant, 1, 246
- Smak Gregoor, 2003, Long-term results of a randomized, prospective study after withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone [abstract]., Am J Transplant, 3, 217
- Jindal, 2002, Reduction of high cholesterol levels by early withdrawal of steroids from a tacrolimus-based triple regimen [abstract]., Am J Transplant, 2, 190
- Pascual, 2004, Long-term efficacy and safety of steroid withdrawal in tacrolimus-treated renal transplant recipients: Results of a 3 year followup., Am J Transplant, 4, 578
- van Hooff, 2001, First, large, prospective study of a controlled withdrawal of steroids or MMF following three months of tacrolimus/MMF/steroid therapy abstract., J Am Soc Nephrol, 12, 920a
- Dudley, 1994, Effect of steroid withdrawal on graft function in renal transplant recipients [abstract]., Nephrol Dial Transplant, 9, 1672
- Hollander, 1996, Late prednisone withdrawal in renal transplant patients [abstract]., J Am Soc Nephrol, 7, 1911
- Matl, 2000, Withdrawal of steroids from the triple-drug therapy in renal transplant patients., Casopis Lekaru Ceskych, 139, 115
- Matl, 1998, Withdrawal of steroids from triple drug therapy in renal transplant patients [abstract]., Nephrol Dial Transplant, 13, A256
- Farmer, 2001, What is the value of short synacthen tests in predicting the ease of steroid withdrawal in renal transplant recipients? A randomised controlled trial [abstract]., Am J Transplant, 1, 190
- Akin, 2004, Five year follow-up after steroid withdrawal demonstrates no evidence of worsening renal function [abstract]., Am J Transplant, 4, 298
Cited by
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Diagnosis and prevention of chronic kidney allograft loss
Nankivell, B. J., & Kuypers, D. R. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60699-5 · Cited by 324
Prevention of cardiovascular disease in adult recipients of kidney transplants
Jardine, A. G., Gaston, R. S., Fellstrom, B. C., & Holdaas, H. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61334-2 · Cited by 281
Steroid avoidance or withdrawal for kidney transplant recipients
Haller, M. C., Royuela, A., Nagler, E. V., Pascual, J., & Webster, A. C. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005632.pub3 · Cited by 258
Walsh, M., Merkel, P. A., Peh, C. A., Szpirt, W., Guillevin, L., Pusey, C. D., deZoysa, J., Ives, N., Clark, W. F., Quillen, K., et al. (2013) · Trials · doi:10.1186/1745-6215-14-73 · Cited by 243
Rangaswami, J., Mathew, R. O., Parasuraman, R., Tantisattamo, E., Lubetzky, M., Rao, S., Yaqub, M. S., Birdwell, K. A., Bennett, W., Dalal, P., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz053 · Cited by 221
Assessment and Management of Hypertension in Transplant Patients
Weir, M. R., Burgess, E. D., Cooper, J. E., Fenves, A. Z., Goldsmith, D., McKay, D., Mehrotra, A., Mitsnefes, M. M., Sica, D. A., & Taler, S. J. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014080834 · Cited by 190
Thomusch, O., Wiesener, M., Opgenoorth, M., Pascher, A., Woitas, R. P., Witzke, O., Jaenigen, B., Rentsch, M., Wolters, H., Rath, T., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32187-0 · Cited by 165
Sarwal, M., Ettenger, R. B., Dharnidharka, V. R., Benfield, M. R., Mathias, R., Portale, A. A., McDonald, R. A., Harmon, W., Kershaw, D. S., Vehaskari, V. M., et al. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04145.x · Cited by 157
“In pediatric transplantation, it is possible to withdraw (21) or avoid steroids (22) if other immunosuppressive agents are given in large doses (18).”
BackgroundThe need for minimization strategies: current problems of immunosuppression
Bamoulid, J., Staeck, O., Halleck, F., Khadzhynov, D., Brakemeier, S., Dürr, M., & Budde, K. (2015) · Transplant International · doi:10.1111/tri.12553 · Cited by 153
Kuo, H., Sampaio, M. S., Vincenti, F. G., & Bunnapradist, S. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.06.027 · Cited by 125
Hypertension in kidney transplant recipients: Hypertension renal transplantation
Ponticelli, C. E., Cucchiari, D., & Graziani, G. (2011) · Transplant International · doi:10.1111/j.1432-2277.2011.01242.x · Cited by 107
“hypertension was significantly reduced in steroid-free patients [32].”
BackgroundComorbidity in inflammatory bowel disease
López–Sanromán, A., & Muñoz, F. (2011) · World Journal of Gastroenterology · doi:10.3748/wjg.v17.i22.2723 · Cited by 112
Pirsch, J. D., Henning, A. K., First, M. R., Fitzsimmons, W., Gaber, A. O., Reisfield, R., Shihab, F., & Woodle, E. S. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13247 · Cited by 95
“A recent meta-analysis of steroid avoidance or withdrawal showed an increased risk of rejection, but no impact on patient or graft survival (20).”
BackgroundLebranchu, Y., Thierry, A., Thervet, É., Büchler, M., Étienne, I., Westeel, P. F., de Ligny, B. H., Moulin, B., Rérolle, J. P., Frouget, T., et al. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03637.x · Cited by 93
Post-transplantation diabetes—state of the art
Sharif, A., & Cohney, S. J. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00387-3 · Cited by 100
Heemann, U. W., Abramowicz, D., Spasovski, G., Vanholder, R. C., & for the European Renal Best Practice (ERBP) Work Group on kidney transplantation (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr169 · Cited by 92
“As the cessation of steroids is associated with a reduction of side effects, there are certainly reasons to justify a reduction or withdrawal of steroids even after the first week [16].”
BackgroundTen-Year Outcome after Rapid Discontinuation of Prednisone in Adult Primary Kidney Transplantation
Rizzari, M. D., Suszynski, T. M., Gillingham, K. J., Dunn, T. B., Ibrahim, H. N., Payne, W. D., Chinnakotla, S., Finger, E. B., Sutherland, D. E. R., Kandaswamy, R., et al. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08630811 · Cited by 86
“(16) (triglycerides, NODM requiring insulin, and weight gain) and Knight and Morris (14) (hypertension, NODM, and hypercholesterolemia).”
BackgroundInfluentialMetabolic consequences of modern immunosuppressive agents in solid organ transplantation
Bamgbola, O. (2016) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018816641580 · Cited by 85
“Patients placed on such steroid-sparing regimen are characterized by higher rate of acute rejection episodes (AREs) and lower allograft function [Zhang et al. 2013; Knight and Morris, 2010].”
BackgroundInfluentialNovel Strategies in Immunosuppression: Issues in Perspective
Webber, A. B., Hirose, R., & Vincenti, F. G. (2011) · Transplantation · doi:10.1097/tp.0b013e3182145306 · Cited by 90
Wissing, K. M., & Pipeleers, L. (2014) · Transplantation Reviews · doi:10.1016/j.trre.2013.12.004 · Cited by 89
Genetics of New-Onset Diabetes after Transplantation
McCaughan, J. A., McKnight, A. J., & Maxwell, A. P. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013040383 · Cited by 86
Approach and Management of Hypertension After Kidney Transplantation
Tantisattamo, E., Molnar, M. Z., Ho, B., Reddy, U. G., Dafoe, D. C., Ichii, H., Ferrey, A., Hanna, R. M., Kalantar‐Zadeh, K., & Amin, A. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00229 · Cited by 96
Claes, K., Meier-Kriesche, H.-U., Schold, J. D., Vanrenterghem, Y., Halloran, P. F., & Ekberg, H. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr238 · Cited by 75
“Current data on the effect of prolonged use of corticosteroids demonstrate a worse metabolic profile, which might be more important than differences between other immunosuppressive agents [43–45].”
BackgroundAssociation Between Steroid Dosage and Death With a Functioning Graft After Kidney Transplantation
Opelz, G., & Döhler, B. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12313 · Cited by 75
“Steroid avoidance or withdrawal results in an improvement in cardiovascular risk factors, notably blood pressure (8), new-onset diabetes (8), dyslipidemia (8) and weight gain (9–13), an effect that appears to be dosedependent (14).”
BackgroundInfluentialLv, C., Zhang, Y., Chen, X., Huang, X., Xue, M., Sun, Q., Wang, T., Liang, J., He, S., Gao, J., et al. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12275 · Cited by 69
Thøfner, L. B., Rostved, A. A., Pommergaard, H., & Rasmussen, A. (2017) · Transplantation Reviews · doi:10.1016/j.trre.2017.03.004 · Cited by 72
Wissing, K. M., Abramowicz, D., Weekers, L. E., Budde, K., Rath, T., Witzke, O., Broeders, N., Kianda, M. N., & Kuypers, D. R. J. (2018) · American Journal of Transplantation · doi:10.1111/ajt.14665 · Cited by 71
Metabolic Syndrome in Kidney Transplantation: Management of Risk Factors
Hricik, D. E. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01200211 · Cited by 67
New-Onset Diabetes After Transplantation (NODAT): An Evaluation of Definitions in Clinical Trials
First, M. R., Dhadda, S., Croy, R., Holman, J., & Fitzsimmons, W. E. (2013) · Transplantation · doi:10.1097/tp.0b013e318293fcf8 · Cited by 67
Steroids in kidney transplant patients
Steiner, R. W., & Awdishu, L. (2011) · Seminars in Immunopathology · doi:10.1007/s00281-011-0259-7 · Cited by 68
“Another careful meta-analysis concluded that steroid withdrawal was associated with an increased rate of rejection as well as increased side effects, but most studies included in the analysis were of poor quality [56].”
ResultKnoll, G. A., Blydt‐Hansen, T. D., Campbell, P. M., Cantarovich, M., Cole, E., Fairhead, T., Gill, J. S., Gourishankar, S., Hébert, D., Hodsman, A. B., et al. (2010) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2010.05.004 · Cited by 69
Baker, R. J., Jardine, A. G., & Andrews, P. (2011) · Nephron Clinical Practice · doi:10.1159/000328074 · Cited by 67
Current trends in immunosuppressive therapies for renal transplant recipients
Lee, R.-A., & Gabardi, S. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110624 · Cited by 70
The role of T hymoglobulin induction in kidney transplantation: an update
Mourad, G., Morélon, E., Noël, C., Glotz, D., & Lebranchu, Y. (2012) · Clinical Transplantation · doi:10.1111/ctr.12021 · Cited by 68
Torres, A., Hernández, D., Moreso, F., Serón, D., Burgos, M. D., Pallardó, L., Kanter, J., Corte, C. D., Rodríguez, M., Díaz, J. M., et al. (2018) · Kidney International Reports · doi:10.1016/j.ekir.2018.07.009 · Cited by 64
“In fact, 3 of the 5 patients with BPAR developed PTDM.”
MethodInfluentialHypertension in the kidney transplant recipient
Wadei, H. M., & Textor, S. C. (2010) · Transplantation Reviews · doi:10.1016/j.trre.2010.02.001 · Cited by 66
Krämer, B. K., Klinger, M., Vitko, S., Głyda, M., Midtvedt, K., Stefoni, S., Citterio, F., Pietruck, F., Squifflet, J., Segoloni, G., et al. (2012) · Transplantation · doi:10.1097/tp.0b013e31825c1d6c · Cited by 61
Diaz-Siso, J. R., Fischer, S., Sisk, G. C., Bueno, E. M., Kueckelhaus, M., Talbot, S. G., Carty, M. J., Treister, N. S., Marty, F. M., Milford, E. L., et al. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13103 · Cited by 56
“vascular outcomes along with higher rates of acute rejections (20).”
BackgroundMourad, G., Głyda, M., Albano, L., Viklický, O., Merville, P., Tydén, G., Mourad, M., Lõhmus, A., Witzke, O., Christiaans, M. H. L., et al. (2016) · Transplantation · doi:10.1097/tp.0000000000001453 · Cited by 53
Immunosuppression and Post-transplant Hyperglycemia
Montero, N., & Pascual, J. (2015) · Current Diabetes Reviews · doi:10.2174/1573399811666150331160846 · Cited by 54
Glucocorticoids use in kidney transplant setting
de Lucena, D. D., & Rangel, É. B. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1530214 · Cited by 58
“were observed in terms of GC resistant AR, patient, or graft survival [99].”
BackgroundNaesens, M., Salvatierra, O., Benfield, M. R., Ettenger, R. B., Dharnidharka, V. R., Harmon, W., Mathias, R., & Sarwal, M. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04144.x · Cited by 47
Chadban, S. J., Eris, J., Kanellis, J., Pilmore, H., Lee, P. C., Lim, S. K., Woodcock, C., Kurstjens, N., Russ, G. R., & the SOCRATES Study Group (2013) · Transplant International · doi:10.1111/tri.12252 · Cited by 46
“Oral corticosteroids incur well-documented complications including osteoporosis, diabetes and cardiovascular disease [10].”
BackgroundPathogenesis and management of hypertension after kidney transplantation
Chatzikyrkou, C., Menne, J., Gwinner, W., Schmidt, B. M. W., Lehner, F., Blume, C. A., Schwarz, A., Haller, H. G., & Schiffer, M. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e32834bd1e7 · Cited by 50
New-onset diabetes after transplantation: Risk factors and clinical impact
Räkel, A., & Karelis, A. D. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2010.09.003 · Cited by 52
“[138] reviewed the ata for steroid avoidance or withdrawal after renal transplantaion and concluded that it is associated with a small increase in he risk of acute rejection (RR: 1.”
BackgroundWoodle, E. S., Gill, J. S., Clark, S. R., Stewart, D. E., Alloway, R. R., & First, R. M. (2021) · JAMA Surgery · doi:10.1001/jamasurg.2020.6929 · Cited by 50
Lv, C., Chen, M., Xu, M., Xu, G., Zhang, Y., He, S., Xue, M., Gao, J., Yu, M., Gao, X., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099406 · Cited by 45
Personalized immunosuppression in elderly renal transplant recipients
Peeters, L. E. J., Andrews, L. M., Hesselink, D. A., de Winter, B. C. M., & van Gelder, T. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.031 · Cited by 48
Favoring the Risk–Benefit Balance for Upper Extremity Transplantation—The Pittsburgh Protocol
Gorantla, V. S., Brandacher, G., Schneeberger, S., Zheng, X. X., Donnenberg, A. D., Losee, J. E., & Lee, W. P. A. (2011) · Hand Clinics · doi:10.1016/j.hcl.2011.08.008 · Cited by 43
Fairfield, C. J., Penninga, L., Powell, J. J., Harrison, E. M., & Wigmore, S. J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007606.pub3 · Cited by 43
Cantarovich, D., Rostaing, L. P. E., Kamar, N., Ducloux, D., Saint-Hillier, Y., Mourad, G., Garrigue, V., Wolf, P., Ellero, B., Cassuto, É., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12866 · Cited by 41
Zhang, H., Zheng, Y., Liu, L., Fu, Q., Li, J., Huang, Q., Liu, H., Deng, R., & Wang, C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146523 · Cited by 43
Non-immunological complications following kidney transplantation
Cohen‐Bucay, A., Gordon, C. E., & Francis, J. M. (2019) · F1000Research · doi:10.12688/f1000research.16627.1 · Cited by 49
Serrano, O. K., Kandaswamy, R., Gillingham, K. J., Chinnakotla, S., Dunn, T. B., Finger, E. B., Payne, W. D., Ibrahim, H. N., Kukla, A., Spong, R., et al. (2017) · Transplantation · doi:10.1097/tp.0000000000001756 · Cited by 38
New-onset diabetes after kidney transplant in children
Garro, R., Warshaw, B. L., & Felner, E. I. (2014) · Pediatric Nephrology · doi:10.1007/s00467-014-2830-7 · Cited by 39
“While there was concern for a mildly increased risk of acute rejection and decreased graft function in steroid avoidance/withdrawal patients, no effect on overall graft or patient survival was observed [50].”
BackgroundPrevention of cardiovascular disease after renal transplantation
Svensson, M. H. S., Jardine, A. G., Fellström, B., & Holdaas, H. (2012) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e3283560a3b · Cited by 37
Kanbay, M., Güldan, M., Özbek, L., Çöpür, S., Covic, A. S., & Covic, A. C. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.07.014 · Cited by 42
Steroid‐freeandsteroid withdrawalprotocols in heart transplantation: the review of literature
Baraldo, M., Gregoraci, G., & Livi, U. (2014) · Transplant International · doi:10.1111/tri.12309 · Cited by 44
Early Steroid Withdrawal in Deceased-Donor Kidney Transplant Recipients with Delayed Graft Function
Bae, S., Garonzik‐Wang, J., Massie, A. B., Jackson, K. R., McAdams‐DeMarco, M., Brennan, D. C., Lentine, K. L., Coresh, J., & Segev, D. L. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019040416 · Cited by 35
Smith, M. W., Cherukuri, A., Newstead, C. G., Lewington, A. J. P., Ahmad, N., Menon, K. V., Pollard, S. G., Prasad, P., Tibble, S., Giddings, E., et al. (2013) · Transplantation · doi:10.1097/tp.0b013e3182a64db9 · Cited by 37
“may yield increased rates of acute rejection, the effect on graft function is minimal, with patient and graft survival remaining unaffected (12) and some evidence that such protocols reduce mortality (13, 14).”
BackgroundSteroid withdrawal after renal transplantation: a retrospective cohort study
Haller, M. C., Kammer, M., Kainz, A., Baer, H. J., Heinze, G., & Oberbauer, R. W. (2017) · BMC Medicine · doi:10.1186/s12916-016-0772-6 · Cited by 34
Kidney transplant outcomes in HIV-positive patients: a systematic review and meta-analysis
Zheng, X., Gong, L., Xue, W., Zeng, S., Xu, Y., Zhang, Y., & Hu, X. (2019) · AIDS Research and Therapy · doi:10.1186/s12981-019-0253-z · Cited by 33
Káposztás, Z., Gyürüs, É., & Kahan, B. D. (2011) · Transplantation Proceedings · doi:10.1016/j.transproceed.2011.04.008 · Cited by 41
Fairfield, C. J., Penninga, L., Powell, J. J., Harrison, E. M., & Wigmore, S. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007606.pub4 · Cited by 43
Sarafidis, P. A., Schmieder, R. E., Burnier, M., Persu, A., Januszewicz, A., Halimi, J., Arıcı, M., Ortíz, A., Wanner, C., Mancia, G., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae041 · Cited by 36
“…treatment with increased BP is emphasized, and partial activation of mineralocorticoid receptors by cortisol causing sodium retention is suggested as a main mechanism [110 ], while glucocorticoid avoidance or withdrawal protocols in KTRs are associated with better BP profile [118 , 119 ].”
BackgroundMeur, Y. L., Thierry, A., Glowacki, F., Rérolle, J.-P., Garrigue, V., Ouali, N., Heng, A.-É., Delahousse, M., Albano, L., Lang, P., et al. (2011) · Transplantation · doi:10.1097/tp.0b013e318234e134 · Cited by 31
“Two recent systematic reviews confirmed that early steroid withdrawal strategies increase the risk of acute rejection (3, 4) Our results indicate that early steroid withdrawal ( 7 days) is feasible and safe in selected patients with a 70% success at 1 year.”
BackgroundSeissler, N., Schmitt, E., Hug, F., Sommerer, C., Zeier, M. G., Schaier, M., & Steinborn, A. (2012) · Transplant Immunology · doi:10.1016/j.trim.2012.09.003 · Cited by 31
Knight, S. R., & Morris, P. J. (2011) · Transplant International · doi:10.1111/j.1432-2277.2011.01335.x · Cited by 30
Self-citationPrevention and management of new-onset diabetes mellitus in kidney transplantation.
Khong, M. J., & Chong, C. P. (2014) · PubMed · Cited by 29
Immunosuppression: Does One Regimen Fit All?
Sprangers, B., Kuypers, D. R. J., & Vanrenterghem, Y. F. C. (2011) · Transplantation · doi:10.1097/tp.0b013e31822094d1 · Cited by 28
Cardiovascular Risk after Kidney Transplantation: Causes and Current Approaches to a Relevant Burden
Reggiani, F., Moroni, G. L., & Ponticelli, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12081200 · Cited by 33
“A systematic review and meta-analysis showed that steroids avoidance or withdrawal is associated with better cardiovascular outcomes at a cost of an increased risk of acute rejections [51].”
BackgroundHypertension in kidney transplant recipients
Alexandrou, M. E., Ferro, C. J., Boletis, I. N., Papagianni, A. A., & Sarafidis, P. A. (2022) · World Journal of Transplantation · doi:10.5500/wjt.v12.i8.211 · Cited by 33
The metabolic syndrome following kidney transplantation
Goldsmith, D. J. A., & Pietrangeli, C. E. (2010) · Kidney International · doi:10.1038/ki.2010.210 · Cited by 31
“aggressive efforts at weaning, are associated with significant elevation in cardiovascular risk.(38,39) Finally, overimmunosuppression attributed to CNIs, particularly after the use of strong induction agents, has been linked to the reactivation of polyomavirus causing BK nephropathy.”
BackgroundCiancio, G., Gaynor, J. J., Zarak, A., Sageshima, J., Guerra, G., Roth, D., Brown, R., Kupin, W. L., Chen, L., Tueros, L., et al. (2010) · Transplantation · doi:10.1097/tp.0b013e3182003d76 · Cited by 28
“Similar results were also reported in a recent meta-analysis (18).”
ResultObesity and Metabolic Syndrome in Kidney Transplantation
LaGuardia, H., & Zhang, R. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0335-6 · Cited by 27
Gaynor, J. J., Ciancio, G., Guerra, G., Sageshima, J., Hanson, L., Roth, D., Goldstein, M. J., Chen, L., Kupin, W. L., Mattiazzi, A. D., et al. (2015) · Clinical Transplantation · doi:10.1111/ctr.12510 · Cited by 27
Krämer, B. K., Montagnino, G., Krüger, B., Margreiter, R., Olbricht, C. J., Marcén, R., Sester, U., Kunzendorf, U., Dietl, K., Rigotti, P., et al. (2015) · Transplant International · doi:10.1111/tri.12716 · Cited by 30
Randomized Trial of Dual Antibody Induction Therapy With Steroid Avoidance in Renal Transplantation
Ciancio, G., Gaynor, J. J., Sageshima, J., Guerra, G., Zarak, A., Roth, D., Brown, R., Kupin, W. L., Chen, L., Hanson, L., et al. (2011) · Transplantation · doi:10.1097/tp.0b013e3182384b21 · Cited by 25
“Similar results were also reported in a recent meta-analysis (42).”
ResultCurrent immunosuppressive treatment after kidney transplantation
Kho, M. M. L., Cransberg, K., Weimar, W. W., & van Gelder, T. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.552428 · Cited by 25
“Patient and graft survival were, however, not affected by steroid avoidance or withdrawal [2].”
BackgroundMetabolic syndrome and non‐alcoholic fatty liver disease after liver or kidney transplantation
Mikolašević, I., Orlić, L., Hrstić, I., & Milić, S. (2015) · Hepatology Research · doi:10.1111/hepr.12642 · Cited by 32
Trial design and endpoints in clinical transplant research
Knight, S. R., Morris, P. J., Schneeberger, S., & Pengel, L. H. M. (2016) · Transplant International · doi:10.1111/tri.12743 · Cited by 26
Self-citationInduction Therapy in Renal Transplant Recipients: A Review
Laftavi, M. R., Sharma, R. K., Feng, L., Said, M., & PANKEWYCZ, O. G. (2014) · Immunological Investigations · doi:10.3109/08820139.2014.914326 · Cited by 26
Uemura, T., Ramprasad, V., Matsushima, K., Shike, H., Valania, T., Kwon, O., Ghahramani, N., Shah, R. A., Farooq, U., Khan, A. S., et al. (2011) · Transplantation · doi:10.1097/tp.0b013e31822b58be · Cited by 24
“Complication SPK (n=17), n (%) PAK (n=5), n (%) PTA (n=6), n (%) Total (n=28), n (%) Acute cellular rejection 8 (47) 1 (20) 3 (50) 12 (42) Antibody-mediated rejection 2 (11) 0 0 2 (7) Donor-specific antibodies 3 (17) 0 0 3 (10) CMV 7 (41) 1 (20) 0 8 (28) BK nephropathy 1 (6) 0 n/a 1 (5) Bacterial infection 7 (41) 1 (2…”
Hernández, D., & Moreso, F. (2013) · PubMed · doi:10.3265/nefrologia.pre2012.nov.11743 · Cited by 28
Risk assessment and management of post-transplant diabetes mellitus
Han, E., Kim, M. S., Kim, Y. S., & Kang, E. S. (2016) · Metabolism · doi:10.1016/j.metabol.2016.07.011 · Cited by 30
“Although early withdrawal or avoidance of corticosteroid therapy has a beneficial effect on hyperglycemia, it also increases the risk of rejection [67].”
Backgroundvan Sandwijk, M. S., de Vries, A. P. J., Bakker, S. J. L., ten Berge, I. J. M., Berger, S. P., Bouatou, Y., de Fijter, J. W., Florquin, S., van der Heide, J. J. H., Idu, M. M., et al. (2018) · Transplantation Direct · doi:10.1097/txd.0000000000000794 · Cited by 22
Ghoneim, M. A., Bakr, M. A., Refaie, A. F., Akl, A. I., Shokeir, A. A., El‐Din, A. B. S., Ammar, H. M., Ismail, A. M., Sheashaa, H. A., & El-Baz, M. A. (2013) · BioMed Research International · doi:10.1155/2013/912413 · Cited by 21
“They concluded that such protocols are justified with current immunosuppressive protocols in low-risk recipients [27].”
BackgroundSæves, I., Line, P., & Bergan, S. (2012) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31825ee3f8 · Cited by 21
“Avoidance or withdrawal of steroids increases the risk of acute rejection but decreases the risks of various side effects.(16,17) It is therefore conceivable that therapeutic drug monitoring of prednisolone could be useful in transplant recipients.”
BackgroundPeracha, J., Nath, J., Ready, A. R., Tahir, S., Parekh, K., Hodson, J. A., Ferro, C. J., Borrows, R., & Sharif, A. (2016) · Transplant International · doi:10.1111/tri.12782 · Cited by 20
“Systematic reviews and meta-analyses of steroid avoidance/withdrawal have demonstrated some improvement of cardio-metabolic parameters (including hyperglycaemia) but increased risk for rejection [23,24].”
BackgroundNehus, E. J., Liu, C., Lü, B., Macaluso, M., & Kim, M. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx193 · Cited by 20
Diabetes mellitus in dialysis and renal transplantation
Ben-David, E., Hull, R., & Banerjee, D. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211048663 · Cited by 23
Management of dyslipidemia in pediatric renal transplant recipients
Bock, M., Wall, L., Dobrec, C., Chandran, M. M., & Goebel, J. (2020) · Pediatric Nephrology · doi:10.1007/s00467-019-04428-y · Cited by 18
Tillmann, F.-P., Schmitz, M., Rump, L. C., & Quack, I. (2017) · International Urology and Nephrology · doi:10.1007/s11255-017-1754-0 · Cited by 19
Muthukumar, T., Afaneh, C. I., Ding, R., Tsapepas, D. S., Lubetzky, M., Jacobs, S. E., Lee, J., Sharma, V., Lee, J., Dadhania, D. M., et al. (2013) · Transplantation · doi:10.1097/tp.0b013e31827ac322 · Cited by 17
“These observations are consistent with the recent meta-analysis showing reductions in the risk of hypertension, new-onset diabetes, and hypercholesterolemia with steroid avoidance or withdrawal after kidney transplantation (34).”
BackgroundResultWeaver, D. J., Selewski, D. T., Janjua, H. S., & Iorember, F. M. (2015) · Pediatric Transplantation · doi:10.1111/petr.12633 · Cited by 17
Early Steroid Withdrawal in Repeat Kidney Transplantation
Mujtaba, M. A., Taber, T. E., Goggins, W. C., Yaqub, M. S., Mishler, D. P., Milgrom, M. L., Fridell, J. A., Lobashevsky, A. L., Powelson, J. A., & Sharfuddin, A. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05110610 · Cited by 17
Immunosuppression and Results in Renal Transplantation
Bamoulid, J., Staeck, O., Halleck, F., Khadzhynov, D., Paliege, A., Brakemeier, S., Dürr, M., & Budde, K. (2016) · European Urology Supplements · doi:10.1016/j.eursup.2016.04.011 · Cited by 17
Prevalence of the metabolic syndrome in kidney transplant recipients: A single-center study
Hami, M., Sabbagh, M. R. P., Sefidgaran, A., & Mojahedi, M. J. (2017) · Saudi Journal of Kidney Diseases and Transplantation · doi:10.4103/1319-2442.202786 · Cited by 22
Metadata
- Authors
- Knight, S. R., & Morris, P. J.
- Affiliations
- University of London (GB)
- Corresponding author
- Morris, Peter J.
- ORCID
- Knight, Simon R.
- Venue
- Transplantation
- Published
- 2010-01-15
- Volume
- 89
- Issue
- 1
- Pages
- 1-14
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W2006211317
- Cited by
- 265
- References
- 113
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 8 · 2023: 14 · 2022: 11 · 2021: 14 · 2020: 10 · 2019: 15 · 2018: 13 · 2017: 17 · 2016: 25 · 2015: 20 · 2014: 26 · 2013: 16 · 2012: 21
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Transplantation (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Nephrology › Renal and Vascular Pathologies
- Keywords
- steroid avoidance, corticosteroid withdrawal, kidney transplantation, acute rejection, corticosteroid-sparing immunosuppression, cardiovascular risk, hypertension, new-onset diabetes, hypercholesterolemia, graft survival, patient survival, serum creatinine
- MeSH terms
- Adrenal Cortex Hormones, Cardiovascular Diseases, Graft Rejection, Humans, Immunosuppressive Agents, Meta-Analysis as Topic, Kidney Transplantation, Survivors, Patient Selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.